Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease

source extracted confidence: high 2026-04-09

Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease

Liu et al., 2021 | Front Aging Neurosci | Systematic Review

Citation

Liu Huanhuan, Zhang Dandan, ... Huang Saie. Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease. Front Aging Neurosci. 2021;13:738971. doi:10.3389/fnagi.2021.738971

Abstract

The changes of neurochemicals in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients has been observed via magnetic resonance spectroscopy in several studies. However, whether it exists the consistent pattern of changes of neurochemicals in the encephalic region during the progression of MCI to AD were still not clear. The study performed meta-analysis to investigate the patterns of neurochemical changes in the encephalic region in the progress of AD. We searched the PubMed, Embase, Cochrane Library, and Web of Science databases, and finally included 63 studies comprising 1,086 MCI patients, 1,256 AD patients, and 1,907 healthy controls. It showed that during the progression from MCI to AD, N-acetyl aspartate (NAA) decreased continuously in the posterior cingulate (PC) (SMD: -0.42 [95% CI: -0.62 to -0.21], z = -3.89, P < 0.05), NAA/Cr (creatine) was consistently reduced in PC (SMD: -0.58 [95% CI: -0.86 to -0.30], z = -4.06, P < 0.05) and hippocampus (SMD: -0.65 [95% CI: -1.11 to -0.12], z = -2.44, P < 0.05), while myo-inositol (mI) (SMD: 0.44 [95% CI: 0.26-0.61], z = 4.97, P < 0.05) and mI/Cr (SMD: 0.43 [95% CI: 0.17-0.68], z = 3.30, P < 0.05) were raised in PC. Furthermore, these results were further verified by a sustained decrease in the NAA/mI of PC (SMD: -0.94 [95% CI: -1.24 to -0.65], z = -6.26, P < 0.05). Therefore, the levels of NAA and mI were associated with the cognitive decline and might be used as potentially biomarkers to predict the possible progression from MCI to AD. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42020200308.

Key Findings

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42020200308.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 63
Age Range See abstract
Condition cognitive

MeSH Terms

  • No MeSH terms indexed

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Systematic Review, Journal Article
  • Vertical: creatine

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09